Jean-Baptiste Guillerme

Learn More
PURPOSE Plasmacytoid dendritic cells (pDC) are antigen-presenting cells specialized in antiviral response. The measles virus vaccine is proposed as an antitumor agent to target and specifically kill tumor cells without infecting healthy cells. EXPERIMENTAL DESIGN Here, we investigated, in vitro, the effects of measles virus vaccine-infected tumor cells on(More)
Antitumor virotherapy using oncolytic viruses (OV) is currently assessed in numerous clinical trials. 1 This therapeutic approach consists of the use of attenuated and/or genetically modified replication-competent virus to preferentially infect and kill tumor cells, with limited infection , if any, of healthy cells. Among the different oncolytic viruses,(More)
Lung and colorectal cancers are responsible for approximately 2 million deaths each year worldwide. Despite continual improvements, clinical management of these diseases remains challenging and development of novel therapies with increased efficacy is critical to address these major public health issues. Oncolytic viruses have shown promising results(More)
Antitumor virotherapy consists of the use of replication-competent viruses to infect and kill tumor cells preferentially, without damaging healthy cells. Vaccine-attenuated strains of measles virus (MV) are good candidates for this approach. Attenuated MV uses the CD46 molecule as a major entry receptor into cells. This molecule negatively regulates the(More)
Four herds of Mbororo Zebu cattle (approximately 40 head each) in traditional situation of the Fulani breeders were treated over a 12 month period. Flumethrin Pour on was first used every three weeks during the rainy season and then deltamethrin Spot on was used every six weeks during the dry season. Pour on treatments might affect the age structure and(More)
Purpose: Plasmacytoid dendritic cells (pDC) are antigen-presenting cells specialized in antiviral response. The measles virus vaccine is proposed as an antitumor agent to target and specifically kill tumor cells without infecting healthy cells. Experimental Design: Here, we investigated, in vitro, the effects of measles virus vaccine–infected tumor cells on(More)
Attenuated measles virus (MV) is currently being evaluated in clinical trials as an oncolytic therapeutic agent. Originally used for its lytic activity against tumor cells, it is now admitted that the effectiveness of MV also lies in its ability to initiate antitumor immune responses through the activation of dendritic cells (DCs). In this study, we(More)
  • 1